(2S,4R)-4-羟基-2-哌啶羧酸甲酯 | 211058-80-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: (2S,4R)-4-羟基-2-哌啶羧酸甲酯
• 英文名称: methyl 4(R)-hydroxypiperidine-2(S)-carboxylate
• 英文别名: methyl cis-4-hydroxy-2-piperidinecarboxylate；methyl (2S,4R)-4-hydroxypiperidine-2-carboxylate
• CAS: 211058-80-9
• 化学式: C₇H₁₃NO₃
• 分子量: 159.185
• InChiKey: XYDFSCGFCFYWNY-RITPCOANSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  58.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (2S,4R)-4-羟基-2-哌啶羧酸甲酯 在 吡啶 、 4-二甲氨基吡啶 、 sodium tetrahydroborate 、 sodium methylate 、 三乙胺 作用下， 以 甲醇 、 二氯甲烷 、 乙腈 为溶剂， 生成 1-O-tert-butyl 2-O-methyl (2S,4S)-4-[(2R)-2-hydroxy-3-methoxy-3-oxopropyl]sulfanylpiperidine-1,2-dicarboxylate
  参考文献：
  名称：

  海胆子房中苦味成分pulcherrimine的所有异构体的合成

  摘要：

  全部八个异构体pulcherrimine的，海胆（的原则苦马粪）卵巢已经被合成，从而导致pulcherrimine的绝对构型的修订。合成的Pulcherrimine和2 S异构体在1.0 mM的浓度下具有很高的苦味。

  DOI：

  10.1016/s0040-4039(01)02095-0
• 作为产物：
  描述：

  (2S,4R)-1-苯甲基2-甲基4-羟基哌啶-1,2-二甲酸基酯 在 palladium on activated charcoal 、 氢气 作用下， 以 乙醇 为溶剂， 反应 16.0h， 以100%的产率得到(2S,4R)-4-羟基-2-哌啶羧酸甲酯
  参考文献：
  名称：

  Discovery and structural diversity of the hepatitis C virus NS3/4A serine protease inhibitor series leading to clinical candidate IDX320

  摘要：

  Exploration of the P2 region by mimicking the proline motif found in BILN2061 resulted in the discovery of two series of potent HCV NS3/4A protease inhibitors. X-ray crystal structure of the ligand in contact with the NS3/4A protein and modulation of the quinoline heterocyclic region by structure based design and modeling allowed for the optimization of enzyme potency and cellular activity. This research led to the selection of clinical candidate IDX320 having good genotype coverage and pharmacokinetic properties in various species. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2015.09.009

文献信息

• [EN] HETEROCYCLIC COMPOUNDS AND METHODS FOR THEIR USE<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES ET LEURS PROCÉDÉS D'UTILISATION
  申请人：SPINIFEX PHARM PTY LTD

  公开号：WO2013110135A1

  公开（公告）日：2013-08-01

  The present invention relates to heterocyclic compounds useful for antagonising angiotensin II Type 2 (AT2) receptor. More particularly the invention relates to piperidine compounds, compositions containing them and their use in methods of treating or preventing disorders or diseases associated with AT2 receptor function including neuropathic pain, inflammatory pain, conditions associated with neuronal hypersensitivity, impaired nerve conduction velocity, cell proliferation disorders, disorders associated with an imbalance between bone resorption and bone formation and disorders associated with aberrant nerve regeneration.

  本发明涉及用于拮抗血管紧张素II型2（AT2）受体的杂环化合物。更具体地，本发明涉及哌啶化合物，含有它们的组合物以及它们在治疗或预防与AT2受体功能相关的疾病或疾病的方法中的使用，包括神经病性疼痛、炎症性疼痛、与神经元过敏、神经传导速度受损、细胞增殖紊乱、骨吸收和骨形成之间失衡以及与异常神经再生相关的疾病。
• MACROCYCLIC SERINE PROTEASE INHIBITORS
  申请人：Parsy Christophe Claude

  公开号：US20100260710A1

  公开（公告）日：2010-10-14

  Provided herein are macrocyclic serine protease inhibitor compounds, for example, of Formula Ia or Ib, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.

  本文提供了大环丝氨酸蛋白酶抑制剂化合物，例如，Ia或Ib式的化合物，包括这些化合物的药物组合物，以及其制备方法。还提供了它们用于治疗宿主HCV感染的方法。
• [EN] CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE<br/>[FR] INHIBITEURS DE LA CÉRAMIDE GALACTOSYLTRANSFÉRASE POUR LE TRAITEMENT DE MALADIES
  申请人：BIOMARIN PHARM INC

  公开号：WO2019104011A1

  公开（公告）日：2019-05-31

  Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the enzyme ceramide galactosyltransferase (CGT), such as, for example, lysosomal storage diseases. Examples of lysosomal storage diseases include, for example, Krabbe disease and Metachromatic Leukodystrophy.

  本发明涉及化合物、制造此类化合物的方法、包含此类化合物的药物组合物和药剂，以及使用此类化合物治疗或预防与鞘氨醇半乳糖基转移酶（CGT）相关疾病或失调的方法，例如，例如，溶酶体贮积病。溶酶体贮积病的例子包括，例如，克拉伯病和异染性脑白质营养不良。
• [EN] PDD AND BPD COMPOUNDS<br/>[FR] COMPOSÉS DDP ET BPD
  申请人：FEMTOGENIX LTD

  公开号：WO2016198869A1

  公开（公告）日：2016-12-15

  The invention relates to pyrridinobenzodiazepines (PDDs) comprising three fused 6-7- 6–membered rings and to benzopyrridodiazecines (BPDs) comprising three fused 6-8- 6–membered rings and, in particular, to PDD or BPD dimers linked together or PDD and BPD monomers linked to aromatic groups, and pharmaceutically acceptable salts thereof, which are useful as medicaments, such as anti-proliferative agents. PDDs and BPDs may be represented by formula (I): and salts or solvates thereof, wherein R2, R4-R6 and R8 are independently selected substituent groups; and either: (i) R9 and R10 together form a double bond; (ii) R9 is H and R10 is OH; or (iii) R9 is H and R10 is ORA and RA is C1-6 alkyl; wherein each of m, n, u and w may be 0 or 1; where (a) the compound is a dimer with each monomer being the same or different and being of formula (I) where one of R1, R2, R3 and R7 of the first monomer and one of R'1, R'2, R3 and R'7 of the second monomer form together a bridge having the formula –X-L-X'- linking the monomers and m + n + u + w = 1; or (b) a dimer and one of R1, R2 and R3 of the first monomer and one of R'1, R'2 and R3 of the second monomer form together a bridge having the formula –X-L-X'- linking the monomers and m = n = u = w = o; or (c) one of R1, R2, R3 and R7 has the formula: –X- L-X'-D or -(CH2)f-O-R14 and m + n + u + w = o or 1; or (d) R7 has the formula: –X-L-X'- D or -(CH2)g-O -15 and m + n + u + w = 1; and X-L-X'- is a linker group and D has the formula (II) or (III):

  该发明涉及到包含三个融合的6-7-6环的吡啶苯二氮杂环己烷（PDDs）以及包含三个融合的6-8-6环的苯基吡啶二氮杂环己烷（BPDs），特别是涉及到连接在一起的PDD或BPD二聚体或连接到芳香基团的PDD和BPD单体，以及其药用可接受盐，这些化合物可用作药物，如抗增殖剂。PDDs和BPDs可以用以下公式（I）表示：以及其盐或溶剂化合物，其中R2、R4-R6和R8是独立选择的取代基团；并且：（i）R9和R10共同形成双键；（ii）R9为H且R10为OH；或（iii）R9为H且R10为ORA，RA为C1-6烷基；其中m、n、u和w中的每个可能为0或1；其中（a）该化合物是一个二聚体，每个单体相同或不同且为公式（I）的其中一个，其中第一个单体的R1、R2、R3和R7中的一个和第二个单体的R'1、R'2、R3和R'7中的一个共同形成具有公式-X-L-X'-的桥连接单体，且m + n + u + w = 1；或（b）一个二聚体，第一个单体的R1、R2和R3中的一个和第二个单体的R'1、R'2和R3中的一个共同形成具有公式-X-L-X'-的桥连接单体，且m = n = u = w = o；或（c）R1、R2、R3和R7中的一个具有以下公式：-X-L-X'-D或-(CH2)f-O-R14，且m + n + u + w = o或1；或（d）R7具有以下公式：-X-L-X'-D或-(CH2)g-O-15，且m + n + u + w = 1；而X-L-X'-是一个连接基团，D具有以下公式（II）或（III）。
• DINUCLEOTIDE COMPOUNDS FOR HCV INFECTION
  申请人：IDENIX PHARMACEUTICALS, INC.

  公开号：US20140112886A1

  公开（公告）日：2014-04-24

  Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds comprise two 2′-methyl nucleotides linked according to Formula I: N 1 -L-N 2 (I) or a pharmaceutically acceptable salt, ester, solvate, stereoisomer, isomeric form, tautomeric form or polymorphic form thereof; wherein N 1 , L and N 2 are as described herein.

  本文提供了用于治疗黄病毒科感染，包括HCV感染的化合物、组合物和方法。在某些实施方式中，披露了核苷类衍生物的化合物和组合物，可以单独或与其他抗病毒药物联合给药。在某些实施方式中，所述化合物包括根据以下式I连接的两个2'-甲基核苷酸：N1-L-N2(I)或其药学上可接受的盐、酯、溶剂合物、立体异构体、同分异构体、互变异构体或其多形形式；其中N1、L和N2如本文所述。